- Centers & Specialties
- Clinical Interests
- Hepatitis B virus (HBV)
- Hepatitis C virus (HCV)
- AIDS and HIV infection
- HIV / HCV coinfection
- Substance abuse
- Travel medicine
- Immunocompromised patient
- Medical Education
- MD, Harvard Medical School
- Residency, Massachusetts General Hospital
- Fellowship, Massachusetts General Hospital
- Board Certifications
- Internal Medicine
- Infectious Disease
- Boston: Massachusetts General Hospital
- Existing Patients
- Patient Gateway
- Insurances Accepted
- Aetna Health Inc.
- AllWays Health (NHP) - ACD
- AllWays Health (NHP) - PBO
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- BMC HealthNet Mass Health MCO/ACO
- Cigna (PAL #'s)
- Commonwealth Care Alliance
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Maine Community Health Options (MCHO)
- Medicare - ACD
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- OSW - Vermont
- Private Health Care Systems (PHCS)
- Railroad Medicare
- Railroad Medicare - ACD
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
- Well Sense Pediatrics
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- Patient Age Group
- Provider Gender
Arthur Kim, M.D. is the Director of the Viral Hepatitis Clinic in the Division of Infectious Diseases at Massachusetts General Hospital and Associate Professor of Medicine at Harvard Medical School. He received his medical degree at Harvard Medical School and trained in internal medicine at MGH and infectious diseases at MGH/Brigham and Women's Hospital. He expresses a longstanding interest in those living with HCV, especially in special populations such as acute infection, prisoners, post-transplantation, and HIV co-infection. He currently is co-PI or co-investigator of NIH-funded studies examining the immunology and immunogenetics of HCV infection. Dr. Kim serves on the AASLD/IDSA committee that provides online guidance at http://hcvguidelines.org. He focuses on HBV, HCV, and HIV/HCV co-infected patients and especially welcomes referrals of those suspected to have early or acute infection and/or with a history of drug use. Dr. Kim also has many years of experience with inpatient transplant infectious disease and outpatient travel advice.
- Research Summary
My research interests are related to hepatitis C virus (HCV) infection in special populations. I have three primary areas of focus:
1. HCV in immunosuppressed humans, including coinfection with HIV-1 and post-transplantation. My interests are in cell-mediated immunity and HCV viral evolution in collaboration with Georg Lauer, Todd Allen
2. Immunology of acute HCV, in collaboration with Georg Lauer of the Gastrointestinal Unit
3. Acute HCV in the MA prisons. As project leader of a U19 NIH Center Grant, I am studying acute HCV in the Massachusetts State Prisons in collaboration with Barbara McGovern at the Lemuel Shattuck Hospital and the Department of Public Health
4. Immunogenetics of HCV infection, in collaboration with Georg Lauer, Ray Chung of the Gastrointestinal Unit, and Mark Daly of the Broad Institute
Selected from 91 publications in Pubmed
- Kim AY, Lauer GM, Ouchi K, et al. The magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend on absolute CD4+ T cell count in individuals coinfected with HIV-1. Blood. 2005;105(3):1170-1178.
- Kim AY, Schulze zur Wiesch J, Kuntzen T, et al. Impaired HCV-specific T cell responses and recurrent HCV in HIV coinfection. PLoS Med. 2006;3(12):e492.
- Kim AY, Kuntzen T, Timm J, et al. Spontaneous control of HCV is associated with the expression of HLA-B*57 and preservation of targeted epitopes. Gastroenterology 2011; 140(2):686-696.
- Kim AY, Nagami EH, Birch CE, et al. A simple strategy to identify acute hepatitis C infection among newly incarcerated injection drug users. Hepatology 2013; 57(3):944-52.
- Kim AY, Onofrey S, Church DR. An epidemiologic update on hepatitis C infection in persons living with or at risk of HIV infection. Journal of Infectious Diseases 2013;207 Suppl 1:S1-6.
- Onofrey S, Aneja J, Haney GA, et al. Underascertainment of acute hepatitis C infections in the U.S. surveillance system: implications for incidence estimates. Annals of Internal Medicine 2015;163(4):254-61.
A new study suggests that massive underreporting may occur within the system set up by the U.S. Centers for Disease Control and Prevention to estimate the incidence of acute hepatitis C virus infection.
55 Fruit Street
Boston, MA 02114-2696
Phone 1: 617-726-3906
Phone 2: 617-724-3230